Prokineticin 2

2008 ◽  
pp. 3291-3291
Keyword(s):  
Neuropeptides ◽  
2018 ◽  
Vol 71 ◽  
pp. 32-42 ◽  
Author(s):  
Roberta Lattanzi ◽  
Daniela Maftei ◽  
Lucia Negri ◽  
Ilaria Fusco ◽  
Rossella Miele

Oncotarget ◽  
2018 ◽  
Vol 9 (53) ◽  
pp. 30079-30091 ◽  
Author(s):  
Yu Yoshida ◽  
Takanori Goi ◽  
Hidetaka Kurebayashi ◽  
Mitsuhiro Morikawa ◽  
Yasuo Hirono ◽  
...  

2018 ◽  
Vol 106 ◽  
pp. 135-143 ◽  
Author(s):  
S. Burroughs ◽  
W.F. Schwindinger ◽  
J.J. Venditti ◽  
T. Trautwein ◽  
A. Dalsania ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Roberta Lattanzi ◽  
Cinzia Severini ◽  
Daniela Maftei ◽  
Luciano Saso ◽  
Aldo Badiani

The prokineticin (PK) family, prokineticin 1 and Bv8/prokineticin 2 (PROK2), initially discovered as regulators of gastrointestinal motility, interacts with two G protein-coupled receptors, PKR1 and PKR2, regulating important biological functions such as circadian rhythms, metabolism, angiogenesis, neurogenesis, muscle contractility, hematopoiesis, immune response, reproduction and pain perception. PROK2 and PK receptors, in particular PKR2, are widespread distributed in the central nervous system, in both neurons and glial cells. The PROK2 expression levels can be increased by a series of pathological insults, such as hypoxia, reactive oxygen species, beta amyloid and excitotoxic glutamate. This suggests that the PK system, participating in different cellular processes that cause neuronal death, can be a key mediator in neurological/neurodegenerative diseases. While many PROK2/PKRs effects in physiological processes have been documented, their role in neuropathological conditions is not fully clarified, since PROK2 can have a double function in the mechanisms underlying to neurodegeneration or neuroprotection. Here, we briefly outline the latest findings on the modulation of PROK2 and its cognate receptors following different pathological insults, providing information about their opposite neurotoxic and neuroprotective role in different pathological conditions.


2010 ◽  
Vol 59 (7-8) ◽  
pp. 589-594 ◽  
Author(s):  
Yan-Cai Xiong ◽  
Xue-Mei Li ◽  
Xue-Jing Wang ◽  
Yu-Qiang Liu ◽  
Fang Qiu ◽  
...  

2016 ◽  
Vol 33 (2) ◽  
pp. 191-199 ◽  
Author(s):  
Katherine J. Burton ◽  
Xiaohan Li ◽  
Baoan Li ◽  
Michelle Y. Cheng ◽  
Henryk F. Urbanski ◽  
...  

Neuron ◽  
2017 ◽  
Vol 95 (1) ◽  
pp. 153-168.e6 ◽  
Author(s):  
Shijia Chen ◽  
Sabine Reichert ◽  
Chanpreet Singh ◽  
Grigorios Oikonomou ◽  
Jason Rihel ◽  
...  
Keyword(s):  

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Cili Zhou ◽  
Jimeng Zhao ◽  
Luyi Wu ◽  
Renjia Huang ◽  
Yin Shi ◽  
...  

It has been proven that prokineticin 2 (PK2) and its receptor PKR2 play an important role in hyperalgesia, while mild moxibustion can relieve visceral hypersensitivity in a rat model of irritable bowel syndrome (IBS). The goal of the present study was to determine the effects of mild moxibustion on the expression of PK2 and PKR2 in colon and spinal cord in IBS rat model, which was induced by colorectal distension using inflatable balloons. After mild moxibustion treatment, abdominal withdrawal reflex (AWR) scores were assessed by colorectal distension; protein and mRNA expression of PK2 and PKR2 in rat colon and spinal cord was determined by immunohistochemistry and fluorescence quantitative PCR. Compared with normal rats, the AWR scores of rats and the expressions of PK2/PKR2 proteins and mRNAs in colon and spinal cord tissue were significantly increased in the model group; compared with the model group, the AWR scores of rats and the expressions of PK2/PKR2 proteins and mRNAs in colon and spinal cord tissue were significantly decreased in the mild moxibustion group. These findings suggest that the analgesia effect of mild moxibustion may be associated with the reduction of the abnormally increased expression of the PK2/PKR2 proteins and mRNAs in the colon and spinal cord.


Sign in / Sign up

Export Citation Format

Share Document